HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

galactoxylomannan

from Cryptococcus neoformans; contains xylose, mannose & galactose

Also Known As:

galactomannoxylan

Networked: 7 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Carbohydrates: 22023
- Polysaccharides: 15383
  - galactoxylomannan: 7

Experts

1.	Casadevall, Arturo: 4 articles (01/2013 - 05/2007)
2.	Chow, Siu-Kei: 2 articles (01/2013 - 02/2011)
3.	De Jesus, Magdia: 2 articles (09/2009 - 05/2007)
4.	Dmitrenok, Andrey S: 1 article (01/2021)
5.	Dorokhova, Vera S: 1 article (01/2021)
6.	Gerbst, Alexey G: 1 article (01/2021)
7.	Komarova, Bozhena S: 1 article (01/2021)
8.	Krylov, Vadim B: 1 article (01/2021)
9.	Nifantiev, Nikolay E: 1 article (01/2021)
10.	Previato, José O: 1 article (01/2021)

Related Diseases

1.	Infections 04/01/2019 - "Our results support the cross-reactivity of cryptococcal galactoxylomannan with the serum GM assay in vitro and in patients with pulmonary cryptococcal infection." 01/01/2021 - "The reported trisaccharide represents the galactoxylomannan moiety first described in 2017, which is the capsular polysaccharide of the opportunistic fungal pathogen Cryptococcus neoformans responsible for life-threatening infections in immunocompromised patients. " 05/01/2007 - "Given the recent report of a false-positive result in the Platelia Aspergillus enzyme immunoassay in a patient with cryptococcosis and in yeast extracts and purified galactoxylomannan of Cryptococcus neoformans, we evaluated culture extracts, purified polysaccharides, clinical specimens, and specimens from animals following experimental infection. "
2.	Cryptococcosis 02/24/2011 - "Evaluation of Cryptococcus neoformans galactoxylomannan-protein conjugate as vaccine candidate against murine cryptococcosis." 05/01/2007 - "Given the recent report of a false-positive result in the Platelia Aspergillus enzyme immunoassay in a patient with cryptococcosis and in yeast extracts and purified galactoxylomannan of Cryptococcus neoformans, we evaluated culture extracts, purified polysaccharides, clinical specimens, and specimens from animals following experimental infection. " 01/01/1984 - "Antibodies against the major capsular polysaccharide of Cryptococcus neoformans, glucuronoxylomannan (GXM), and a minor secreted polysaccharide, galactoxylomannan (GalXM), were surveyed by indirect enzyme immunoassay (EIA) in patients with cryptococcosis, with other mycoses, and in normal controls. "
3.	Paralysis (Palsy) 09/15/2009 - "Galactoxylomannan-mediated immunological paralysis results from specific B cell depletion in the context of widespread immune system damage."
4.	Mycoses (Diseases, Fungus) 01/01/1984 - "Antibodies against the major capsular polysaccharide of Cryptococcus neoformans, glucuronoxylomannan (GXM), and a minor secreted polysaccharide, galactoxylomannan (GalXM), were surveyed by indirect enzyme immunoassay (EIA) in patients with cryptococcosis, with other mycoses, and in normal controls. "
5.	Rheumatoid Arthritis 01/01/2013 - "The microbial capsular polysaccharide galactoxylomannan inhibits IL-17A production in circulating T cells from rheumatoid arthritis patients."

Related Drugs and Biologics

1.	Polysaccharides (Glycans)
2.	Enzymes
3.	Interleukin-17 (Interleukin 17)
4.	Vaccines
5.	Trisaccharides
6.	Proteins (Proteins, Gene)
7.	Antibodies
8.	glucuronoxylomannan